It’s no secret that clinical trials are taking longer than ever: The typical non-oncology drug can spend anywhere from 5.9 to 7.2 years in the clinic before it gets to market—if it gets approved at all. In addition, many drugs require an average of up to three different trials, in each of four phases, to confirm drug safety and efficacy.
With so much effort and energy required to get a trial from planning to completion just as a baseline, it’s important to avoid delays as much as possible. Unfortunately, most sponsors fail to identify and address the warning signs of delay in a systematic way.